Press release
Age-related Macular Degeneration Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Age-related Macular Degeneration Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Age-related Macular Degeneration Pipeline Outlook Report [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key takeaways from the Age-related Macular Degeneration Pipeline Report
* In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
* In July 2025, Hoffmann-La Roche announced a study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
* In July 2025, Innostellar Biotherapeutics Co. Ltd conducted a Phase 2, multi-center, randomized controlled study, subjects will be randomized to receive one of the two dose levels of LX102 (n=20 for each dose level), or aflibercept (n=10). Safety, tolerability, and efficacy will be evaluated for a period of approximately 1 year from baseline.
* DelveInsight's Age-related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Age-related Macular Degeneration treatment.
* The leading Age-related Macular Degeneration Companies such as AbbVie, RemeGen, Stealth BioTherapeutics, Theratocular Biotek, Novartis Pharmaceuticals, Clearside Biomedical, BenoBio, Chengdu Origen Biotechnology Co., Ltd, Surrozen, Anida Pharma, Belite Bio, Inc, Luxa Biotechnology LLC and others.
* Promising AMD Pipeline Therapies such as rhuFab V2 (ranibizumab), Iptacopan (LNP023), VOY-101, bevacizumab, ranibizumab, KH658, Anecortave Acetate, Brolucizumab and others.
Discover how the Age-related Macular Degeneration treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Age-related Macular Degeneration Clinical Trials and Studies [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Emerging Drugs Profile
* Surabgene Lomparvovec: AbbVie
Surabgene Lomparvovec (ABBVRGX314) is an investigational one-time gene therapy being developed by AbbVie in collaboration with REGENXBIO. It utilizes an AAV8 viral vector to deliver a gene encoding an anti-VEGF monoclonal antibody fragment, aiming to inhibit abnormal blood vessel growth in the retina. The therapy is being evaluated in both subretinal and suprachoroidal delivery formats for chronic retinal conditions such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Interim Phase 2 data have shown promising results, including a significant reduction (up to 97%) in the need for supplemental anti-VEGF injections and stable visual acuity outcomes. Two pivotal Phase 3 trials-ATMOSPHERE (subretinal delivery) and ASCENT (suprachoroidal delivery)-are currently ongoing, with topline data expected in 2026. Currently, the drug is in the Phase III stage of its development for the treatment of Age Related Macular Degeneration.
* Elamipretide Stealth BioTherapeutics
Elamipretide, developed by Stealth BioTherapeutics, is a mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, thereby enhancing ATP production and reducing oxidative stress . Currently in late-stage development across several indications, it is the subject of the global PhaseIII ReNEW trial for dry age-related macular degeneration (AMD), evaluating daily subcutaneous dosing to slow photoreceptor loss, with topline data expected in 2026. Earlier PhaseII results supported the FDA's recognition of ellipsoid zone attenuation as a valid endpointand elamipretide holds Fast Track designation for dry AMD, its application for Barth syndrome is under FDA review after a recent resubmission request, with the agency showing openness to accelerated approval based on muscle-strength endpoints.
* Iptacopan: Novartis Pharmaceuticals
Iptacopan (LNP023) is an oral complement factor B inhibitor being developed by Novartis as a potential treatment for early to intermediate age-related macular degeneration (AMD), aimed at reducing progression to late-stage disease. It is currently in a Phase II, randomized, placebo-controlled proofofconcept trial, enrolling patients aged greater than or equal to 50 who have early/intermediate AMD in one eye and neovascular AMD in the other; the study's primary goal is to prevent progression to atrophy or late-stage AMD over two years. As an oral therapy, it offers a major advantage over current intravitreal treatments by potentially improving patient compliance, convenience, and safety in elderly populations eliminating injection-related risks. Currently, the drug is in the Phase II stage of its development for the treatment of Age Related Macular Degeneration.
* BBRP 11001: BenoBio
BBRP11001, also known as BBC1501, is an investigational small-molecule inhibitor developed by BenoBio that targets BET (bromodomain and extra-terminal) proteins. It is designed to modulate epigenetic mechanisms underlying inflammation and angiogenesis, making it a promising candidate for the treatment of neovascular (wet) age-related macular degeneration (AMD). The therapy is currently undergoing a Phase I dose-escalation clinical trial (NCT05803785) in Australia, where it is being evaluated for safety, tolerability, and preliminary efficacy in patients who have shown inadequate response to standard anti-VEGF treatments. Administered via intravitreal injection, BBRP11001 is being tested in ascending doses ranging from 1.25 g to 5 g. Following the initiation of this first-in-human trial in mid-2024, a Phase 2 study is anticipated in 2025. If successful, BBRP11001 could offer a novel, epigenetically driven therapeutic option for managing chronic retinal diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Age Related Macular Degeneration.
* SZN 8143: Surrozen
SZN 8143 is an innovative trispecific antibody candidate from Surrozen, leveraging their Wnt pathway-modulating SWAP Trademark platform to address serious retinal diseases. It uniquely combines Fzd4 agonism, VEGF antagonism, and IL 6 antagonism, aiming to not only suppress pathological angiogenesis but also promote healthy vessel regrowth and reduce inflammation-offering potential therapeutic advantages over standard anti VEGF monotherapy in diabetic macular edema, wet AMD, and uveitic macular edema. Currently in advanced preclinical development, Surrozen is preparing to advance SZN 8143 toward IND-enabling studies alongside its sister candidate SZN 8141, supported by a focused $175million funding round aimed at accelerating these ophthalmology programs. Given its trispecific mechanism and strategic development plan, SZN 8143 represents a hopeful new approach to treating retinopathies with multifaceted pathological components. Currently, the drug is in the Preclinical stage of its development for the treatment of Age Related Macular Degeneration.
The Age-related Macular Degeneration pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Age-related Macular Degeneration with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Age-related Macular Degeneration Treatment.
* Age-related Macular Degeneration Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Age-related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Age-related Macular Degeneration market.
Get a detailed analysis of the latest innovations in the Age-related Macular Degeneration pipeline. Explore DelveInsight's expert-driven report today! @ Age-related Macular Degeneration Unmet Needs [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Companies
AbbVie, RemeGen, Stealth BioTherapeutics, Theratocular Biotek, Novartis Pharmaceuticals, Clearside Biomedical, BenoBio, Chengdu Origen Biotechnology Co., Ltd, Surrozen, Anida Pharma, Belite Bio, Inc, Luxa Biotechnology LLC and others.
Age-related macular degeneration (AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Age-related Macular Degeneration Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Age-related Macular Degeneration Developments @ Age-related Macular Degeneration Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Age-related Macular Degeneration Pipeline Report
* Coverage- Global
* Age-related Macular Degeneration Companies- AbbVie, RemeGen, Stealth BioTherapeutics, Theratocular Biotek, Novartis Pharmaceuticals, Clearside Biomedical, BenoBio, Chengdu Origen Biotechnology Co., Ltd, Surrozen, Anida Pharma, Belite Bio, Inc, Luxa Biotechnology LLC and others.
* AMD Pipeline Therapies- rhuFab V2 (ranibizumab), Iptacopan (LNP023), VOY-101, bevacizumab, ranibizumab, KH658, Anecortave Acetate, Brolucizumab and others.
* Age-related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Age-related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Age-related Macular Degeneration drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Age-related Macular Degeneration Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Age-related macular degeneration (AMD): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Age-related macular degeneration (AMD)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Surabgene Lomparvovec: AbbVie
* Mid Stage Products (Phase II)
* Iptacopan: Novartis Pharmaceuticals
* Early Stage Products (Phase I)
* BBRP 11001: BenoBio
* Preclinical and Discovery Stage Products
* SZN 8143: Surrozen
* Inactive Products
* Age-related macular degeneration (AMD) Key Companies
* Age-related macular degeneration (AMD) Key Products
* Age-related macular degeneration (AMD)- Unmet Needs
* Age-related macular degeneration (AMD)- Market Drivers and Barriers
* Age-related macular degeneration (AMD)- Future Perspectives and Conclusion
* Age-related macular degeneration (AMD) Analyst Views
* Age-related macular degeneration (AMD) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-pipeline-outlook-report-2025-key-70-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-related Macular Degeneration Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4128725 • Views: …
More Releases from ABNewswire
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise…
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card.
The book draws on Zeitoun-Sedki's years of representing individuals and families from…
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity.
Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg
Automotive OBD Products and Application Scenarios
As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions…
More Releases for Age
Easy Age Calculator Introduces Tree Age Calculator for Nature Insights
Trees are often called the "silent witnesses of history." They stand tall for decades, centuries, and sometimes even thousands of years, quietly recording changes in climate, culture, and environment. Today, Easy Age Calculator, a trusted online hub for age-related tools, has launched its Tree Age Calculator, an innovative digital tool that allows people to estimate the age of trees in a safe, accessible, and accurate way.
This launch reflects the company's…
Dark Age Defense Survival Guide
Get Dark Age Defense For A Very Special Price >> https://rebrand.ly/2f043b
People should know how to keep themselves and their families safe, especially in times like this where there is a high probability of natural disasters, power blackouts, wars, and other severe conditions.
The Dark Age Defense is a digital survival aid that provides users with detailed information on various topics including how to create electricity and keep your household appliances…
Adult Milk Powder Market Introducing New Industry Dynamics Through Swot Analysis …
LOS ANGELES, UNITED STATES - The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Adult Milk Powder market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Adult Milk Powder Market. We have provided deep analysis of…
Tattoo Ink Market Size, By Type (Black & Grey Tattoo Ink, Colour Tattoo Ink), By …
Global demand for tattoo ink market was valued at approximately USD 80 million in 2018 and is expected to generate revenue of around USD 142 million by end of 2025, growing at a CAGR of around 5.7% between 2019 and 2025.
A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Tattoo Ink Market. On the basis of historic growth analysis and current…
Age Discrimination
Age Discrimination looks at how both young and old can be penalised by prejudice against their age group. This comprehensive new book is essential to practitioners responsible for HR issues, finance, operations, service delivery, quality and customer relations, and for those with a policy focus or academic interest in diversity issues.
Gower is recognised as one of the world's leading publishers of specialist business and management books and resources. Our publishing…
Victorian Age Meets Digital Age
The digital age is entering the elegant Victorian age Eurocentres school building. In some classrooms interactive whiteboards have been installed and are now being intensively used with language students from all over the world.
The interactive whiteboards have been helping classes become much more exciting and closer to real life. This user-friendly technology enables students to better engage with and discuss up-to-date news or life-style features, enjoy playful grammar exercises,…
